Final NICE guidance for juvenile ideopathic arthritis (JIA)

The National Institute for Health and Care Excellence (NICE) has published final guidance recommending: abatacept (Orencia; Bristol-Myers Squibb); adalimumab (Humira; AbbVie); etanercept (Enbrel; Pfizer); and tocilizumab (RoActemra; Roche), within their marketing authorisations, as options for treating juvenile ideopathic arthritis.

follow the link..

2 Replies

  • Can you actually post the article, as you have to register to sign in with the pharmaceutical journal to read it.

  • Ah. sorry about that. I will rectify ASAP!